

RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED MARCH 31, 2023

(Rs. in Lakhs)

Particulars	Quarter ended			Year ended	
	31-03-2023	31-12-2022	31-03-2022	31-03-2023	31-03-2022
	Audited	Unaudited	Audited	Audited	Audited
1 Revenue from Operations	11,849	13,060	10,380	51,281	44,016
2 Other Income	184	51	126	480	299
3 Total Income (1+2)	12,033	13,111	10,506	51,761	44,315
4 Expenses					
(a) Cost of Materials Consumed	2,242	2,026	2,301	8,612	8,813
(b) Purchases of Stock-in-Trade	2,026	2,539	1,659	9,205	7,890
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-				
	(319)	(318)	(339)	(730)	(2,521)
(d) Employee Benefits Expense	3,377	2,829	2,504	11,706	9,997
(e) Finance Costs	5	7	6	31	52
(f) Depreciation and Amortisation Expense	389	391	378	1,550	1,566
(g) Other Expenses	2,932	3,063	2,904	12,219	11,201
Total Expenses	10,652	10,537	9,413	42,593	36,998
5 Profit before tax (3-4)	1,381	2,574	1,093	9,168	7,317
6 Income tax expenses					
a. Current Tax	369	692	410	2,435	2,276
b. Deferred Tax	(23)	(29)	(69)	(31)	(107)
7 Profit for the period (5-6)	1,035	1,911	752	6,764	5,148
8 Other Comprehensive Income					
(i) Items that will not be reclassified to Profit or Loss	36	(9)	(24)	9	(36)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	(9)	3	8	(2)	11
Other Comprehensive Income Net of Tax	27	(6)	(16)	7	(25)
9 Total Comprehensive Income for the period (7+8)	1,062	1,905	736	6,771	5,123
10 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323
11 Other Equity				29,437	24,254
12 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):					
(a) Basic (in Rs.)	6.26	11.56	4.55	40.90	31.13
(b) Diluted (in Rs.)	6.26	11.56	4.55	40.90	31.13

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on April 28, 2023.
- The Company operates in only one reportable business segment i.e. Pharmaceuticals.
- During the quarter ended 30th June 2022, the Company exercised the option of lower tax rate under section 115 BAA of Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019 effective April 01, 2022. Accordingly, the Company has adopted the new tax rate of 25.17% which has resulted in a reversal of deferred tax balances of Rs 46 lakhs on account of remeasurement of deferred tax balances as at 31st March, 2022.
- Figures for the quarter ended March 31, 2023 and the corresponding quarter in the previous year as reported in the financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also the figures upto the end of the third quarter had only been reviewed and not subjected to audit.
- The Board of Directors has recommended a final dividend of Rs. 12 (Rupees Twelve only) per equity share (150% on the face value of Rs 8 each) for the financial year 2022-23, subject to the approval of shareholders at the ensuing Annual General Meeting.

For RPG Life Sciences Limited

Yugal Sikri
Managing Director
Mumbai, April 28, 2023

Audited Balance Sheet as at March 31, 2023

(Rs. in Lakhs)

Particulars	As at March 31, 2023 (Audited)	As at March 31, 2022 (Audited)
ASSETS		
<u>Non-current assets</u>		
Property, plant and equipment (Including Right of use assets)	10,127	7,464
Capital work-in-progress	1,503	2,545
Other intangible assets	2,299	2,907
Intangible assets under development	1,041	561
Financial assets		
i. Loans	18	16
ii. Other financial assets	44	38
Current Tax asset (Net)	173	121
Other non-current assets	325	118
Total non-current assets	15,531	13,770
<u>Current assets</u>		
Inventories	9,505	8,299
Financial assets		
i. Investments	5,844	-
ii. Loans	2	2
iii. Trade receivables	3,743	3,299
iv. Cash and cash equivalents	2,482	5,694
v. Bank balances other than (iv) above	3,222	1,332
vi. Other financial assets	135	149
Other current assets	1,473	1,916
Total current assets	26,405	20,691
Total assets	41,936	34,461
<u>EQUITY AND LIABILITIES</u>		
<u>Equity</u>		
Equity share capital	1,323	1,323
Other equity	29,437	24,254
Total equity	30,760	25,577
<u>LIABILITIES</u>		
<u>Non-current liabilities</u>		
Financial liabilities		
i. Borrowings	-	1
ii. Lease liabilities	-	29
iii. Other financial liabilities	302	313
Provisions	398	304
Deferred tax liabilities (Net)	197	226
Total non-current liabilities	897	873
<u>Current liabilities</u>		
Financial liabilities		
i. Borrowings	1	28
ii. Lease liabilities	-	36
iii. Trade payables		
(a) total outstanding dues of micro enterprises and small enterprises	482	345
(b) total outstanding dues of creditors other than micro enterprises and small enterprises	5,987	4,205
iv. Other financial liabilities	2,002	1,388
Provisions	1,186	1,415
Current tax liabilities (Net)	-	38
Other current liabilities	620	556
Total current liabilities	10,279	8,011
Total liabilities	11,176	8,884
Total equity and liabilities	41,936	34,461

Audited statement of cash flows for the year ended March 31, 2023

(Rs. in Lakhs)

	Particulars	For the period ended	For the period ended
		March 31, 2023	March 31, 2022
		Audited	Audited
A	Cash Flow from operating activities		
	Profit before income tax	9,168	7,317
	Adjustments for		
	Add:		
	Depreciation and amortisation expenses	1,550	1,566
	Finance costs	31	52
	Loss on disposal of property, plant and equipment	78	-
	Unrealised exchange rate difference	46	(47)
	Provision for Doubtful Debts and Advances (Net)	50	9
	Interest received	(273)	(133)
	Provisions no longer required and written back	(7)	(4)
	Gain on sale of investments	(144)	(89)
		10,499	8,671
	Working capital adjustments:		
	Increase / (Decrease) in trade receivables	(540)	2,481
	Increase / (Decrease) in financial assets - Loans	(8)	(10)
	Increase / (Decrease) in other non-current assets	-	40
	Increase / (Decrease) in other financial assets	14	(35)
	Increase / (Decrease) in other current assets	443	(95)
	Increase / (Decrease) in inventories	(1,206)	(2,466)
	(Increase) / Decrease in trade payables	1,926	(191)
	(Increase) / Decrease in other financial liabilities	539	44
	(Increase) / Decrease in provisions	(126)	9
	(Increase) / Decrease in other current liabilities	64	(88)
	Cash generated from operations	11,606	8,360
	Income taxes paid	(2,523)	(1,885)
	Net cash inflow from operating activities	9,083	6,475
B	Cash flow from investing activities:		
	Acquisition of property, plant and equipment and Intangible assets	(3,274)	(2,395)
	Proceeds from sale of property, plant and equipment and Intangible assets	8	-
	Movement in Other bank balances (Net)	(1,890)	(7)
	Investment in Mutual Funds	(5,700)	
	Investment in Bank Fixed Deposit	-	(1,286)
	Interest received	273	133
	Net gain on sale of investments	-	89
	Net cash (outflow) from investing activities	(10,583)	(3,466)
C	Cash flow from financing activities		
	Proceeds from/ (Repayment of) long term borrowings	(7)	(11)
	Proceeds from/ (Repayment of) Short-term Borrowings	(21)	(31)
	Interest paid	(27)	(37)
	Repayment of principal portion of lease liability	(65)	(66)
	Interest paid on lease liability	(4)	(15)
	Dividend paid	(1,588)	(1,191)
	Net cash (outflow) from financing activities	(1,712)	(1,351)
	Net (decrease)/increase in cash and cash equivalents	(3,212)	1,658
	Add: Cash and cash equivalents at the beginning of the financial period	5,694	4,036
	Cash and cash equivalents at the end of the period	2,482	5,694